{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:00:52Z","timestamp":1791295252003,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1053\/j.seminoncol.2004.02.015","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T13:58:14Z","timestamp":1131026294000},"page":"99-105","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S4","title":["Multiple myeloma: The role of transplant and novel treatment strategies"],"prefix":"10.1053","volume":"31","author":[{"given":"Jonathan","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2004.02.015_BIB1","series-title":"Clinical Oncology","first-page":"2597","article-title":"Multiple myeloma and related disorders","author":"Kyle","year":"2000"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2165\/00003495-200363160-00001","article-title":"Breakthroughs in the management of multiple myeloma","volume":"63","author":"Heffner","year":"2003","journal-title":"Drugs"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1034\/j.1600-065X.2003.00053.x","article-title":"Novel therapeutic approaches for multiple myeloma","volume":"194","author":"Hideshima","year":"2003","journal-title":"Immunol Rev"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB4","first-page":"474a","article-title":"Cellular adhesion inhibits CD95\/FAS mediated apoptosis by altering the intracellular localization and availability of c-FLIPl","volume":"98","author":"Shain","year":"2001","journal-title":"Proc Am Soc Clin Hematol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB5","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","article-title":"The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0093-7754(01)90025-9","article-title":"Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis","volume":"28","author":"Munshi","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s002770000236","article-title":"Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma","volume":"79","author":"Sezer","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0093-7754(01)90033-8","article-title":"Novel therapies targeting the myeloma cell and its bone marrow microenvironment","volume":"28","author":"Hideshima","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB9","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.V85.11.3077.bloodjournal85113077","article-title":"Autologous stem cell transplantation after first remission induction treatment in multiple myeloma","volume":"85","author":"Harousseau","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1200\/JCO.1994.12.4.759","article-title":"High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma","volume":"12","author":"Cunningham","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB11","first-page":"71","article-title":"Bone marrow transplantation in multiple myeloma","volume":"7","author":"Barlogie","year":"1991","journal-title":"Bone Marrow Transplantation"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB13","series-title":"Role of Transplantation in Myeloma","author":"Harousseau","year":"2002"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB16","first-page":"5a","article-title":"Double autologous transplantation improves survival of multiple myeloma patients","volume":"100","author":"Attal","year":"2002","journal-title":"Proc Am Soc Clin Hematol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702826","article-title":"Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma","volume":"27","author":"Bjorkstrand","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB18","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB19","first-page":"178a","article-title":"Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma","volume":"100","author":"Brinker","year":"2002","journal-title":"Proc Am Soc Clin Hematol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/107327489800500304","article-title":"Hematopoietic cell transplantation for multiple myeloma","volume":"5","author":"Bensinger","year":"1998","journal-title":"Cancer Control"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB21","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","article-title":"High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions","volume":"97","author":"Badros","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB22","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB23","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB26","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB27","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","article-title":"DTPACE","volume":"21","author":"Lee","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006321828515","article-title":"Proteasome inhibition","volume":"18","author":"Adams","year":"2000","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB29","first-page":"2615","article-title":"Proteasome inhibitors","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB30","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB31","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB32","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB33","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB34","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3816\/CLM.2003.n.022","article-title":"A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, Velcade) and melphalan in patients with relapsed or refractory multiple myeloma","volume":"4","author":"Yang","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB36","first-page":"775a","article-title":"A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM)","volume":"98","author":"Richardson","year":"2001","journal-title":"Proc Am Soc Clin Hematol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB37","first-page":"775a","article-title":"Results of a phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT)","volume":"98","author":"Zangari","year":"2001","journal-title":"Proc Am Soc Clin Hematol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB38","first-page":"104a","article-title":"A Multi-center, randomized, phase II study to evaluate the efficacy and safety of two CDC-5013 dose regimens when used alone or in combination with dexamethasone (DEX) for the treatment of relapsed or refractory multiple myeloma (MM)","volume":"100","author":"Richardson","year":"2002","journal-title":"Proc Am Soc Clin Hematol"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB39","first-page":"1041","article-title":"Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients","volume":"59","author":"Rousselot","year":"1999","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB40","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1182\/blood.V98.3.805","article-title":"Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells","volume":"98","author":"Grad","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB41","first-page":"851","article-title":"Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"1","author":"Hayashi","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB42","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2402599","article-title":"Clinical activity of arsenic trioxide for the treatment of multiple myeloma","volume":"16","author":"Munshi","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2004.02.015_BIB43","first-page":"3658","article-title":"Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed\/refractory multiple myeloma","volume":"8","author":"Bahlis","year":"2002","journal-title":"Clin Cancer Res"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404000740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404000740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:05:17Z","timestamp":1586538317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775404000740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":43,"alternative-id":["S0093775404000740"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.02.015","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}